Contact Us

Follow

The Idealistic Genius

Duggan Investments is a hands-on, active investment company, headed by Robert Duggan, who has many decades of success and experience.

An example: Under Bob’s guidance, Pharmacyclics' stock price increased from $0.57 a share in Feb 2009, to $261.25 a share in May 2015. Pharmacyclics and its "miracle drug" IMBRUVICA® were acquired by AbbVie for $21 billion in May 2015. As of today, IMBRUVICA® continues its dramatic growth and success, with use in widening indications.

Duggan Investments’ current projects are focused on cutting-edge biosciences. These include groundbreaking developments in cancer treatment, anti-microbial advancements, anti-aging technologies, and stem cell research.

Selective. Results-driven. Successful. Dedicated to making a difference for the betterment of all involved. That’s Duggan Investments.

About Bob

Recent Projects

Duggan Investments focuses on groundbreaking bioscience companies. With cancer treatment, anti-microbial treatment, anti-aging, and stem cell research, our involvement with these cutting-edge technologies is to improve life for all.

Patient-friendly new era standard of care for infectious disease

Summit Therapeutics

Innovations that improve & extend patients' lives

Pulse Biosciences

New ways to fight diseases associated with aging

Human Longevity Inc

New age-related regenerative medicine

OxStem

The conditions of life can and need to improve for the betterment of all involved.

Bob Duggan

Founder

Please feel free to contact us directly for general inquires or media.

Contact Us Media Inquiries